FORM 8-K 
 
 
                   SECURITIES AND EXCHANGE COMMISSION 
 
                         WASHINGTON, D.C. 20549 
  
 
 
                            CURRENT REPORT 
                  Pursuant to Section 13 or 15(d) of 
                  the Securities Exchange Act of 1934 
 
 
 
                            June 26, 1996 
                            Date of Report 
                   (Date of earliest event reported) 
 
 
 
                    BIOJECT MEDICAL TECHNOLOGIES INC. 
         (Exact name of registrant as specified in its charter) 
 
 
 
            Oregon                                    0-15360        
  (State or other jurisdiction                 (Commission File No.) 
of incorporation or organization) 
 
                                 93-1099680 
                         (I.R.S. Employer I.D. No.) 
  
                          7620 S.W. Bridgeport Road 
                              Portland, Oregon                   
                  (Address of principal executive offices) 
         
                                   97224 
                                 (Zip Code) 
               
                              (503) 639-7221 
            (Registrant's telephone number including area code) 
 
 

 
ITEM 5.  OTHER EVENTS 
 
The Company has been developing a self-injection system for Schering AG, 
German, under a multi-year contract signed in March 1994.  On June 26, 1996, 
the Company and Schering entered into a Supply Agreement which specifies the 
terms under which the Company will manufacture and sell the self-injection 
systems to Schering.  Subject to Schering's satisfaction with certain product 
test results and receipt of regulatory approval in the United States and 
certain foreign countries, Bioject will manufacture the self-injection systems 
exclusively for Schering AG which will distribute the systems on a worldwide 
basis to multiple sclerosis patients using Betaseron.  The agreement extends 
for an initial term of eight years and provides for minimum amounts which must 
be produced by Bioject and which must be purchased by Schering AG in order for 
both parties to maintain their rights under the agreement.  The Company has 
commenced preparation to manufacture the self-injection systems, and initial 
shipments under the agreement are scheduled to commence in the first quarter 
of fiscal 1998. 

ITEM 7.  EXHIBITS 
 
10.32	   Supply Agreement between Schering Aktiengesellschaft and Bioject  
Inc. dated June 26, 1996.  Confidential treatment has been requested with  
respect to certain portions of this exhibit pursuant to an Application for  
Confidential Treatment filed with the Commission under Rule 24b-2(b) under the  
Securities Exchange Act of 1934, as amended.  
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the  
registrant has duly caused this report to be signed on its behalf by the  
undersigned, thereunto duly authorized. 
 
 
DATED this 1st day of July, 1996. 
 
 
 
BIOJECT MEDICAL TECHNOLOGIES INC. 
 
 
By   /s/ Peggy J. Miller 
     _____________________________ 
     Peggy J. Miller 
     Vice President, 
     Chief Financial Officer 
     and Secretary